Improving Control of Antibiotic-Resistant Gonorrhea by Integrating Research Agendas Across Disciplines: Key Questions Arising From Mathematical Modeling

Journal of Infectious Diseases

Volumn 213, Issue 6, 2016, Pages 883-890

  Grad, Yonatan H ^a,b   Goldstein, Edward ^a   Lipsitch, Marc ^a   White, Peter J ^c,d,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antibiotic resistance; gonorrhea; immunity; mathematical modeling; Neisseria gonorrhoeae; sexually transmitted infections; vaccine

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BEHAVIOR CHANGE; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DISEASE DURATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG TREATMENT FAILURE; DRUG USE; GONORRHEA; HEALTH PROMOTION; HIGH RISK BEHAVIOR; HUMAN; INFECTION CONTROL; MATHEMATICAL MODEL; MOLECULAR DIAGNOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; BIOLOGICAL MODEL; DRUG EFFECTS; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; MODELS, BIOLOGICAL; NEISSERIA GONORRHOEAE;

EID: 84964878595     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv517     Document Type: Review

References (51)

1. Lax E. The mold in Dr. Florey's coat: the story of the penicillin miracle. 1st ed. New York: H. Holt, 2004.
2. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366:485-7.
3. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40:187-93.
4. Department of Reproductive Health and Research, World Health Organization (WHO). Global incidence and prevalence of selected curable sexually transmitted infections: 2008. Geneva: WHO, 2012. http://www.who.int/reproductivehealth/publications/rtis/2008-STI-estimates.pdf. Accessed 8 February 2013.
5. Head MG, Fitchett JR, Cooke MK, Wurie FB, Hayward AC, Atun R. UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect Dis 2013; 13:55-64.
6. Jerse AE, Bash MC, Russell MW. Vaccines against gonorrhea: current status and future challenges. Vaccine 2014; 32:1579-87.
7. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014.
8. Hethcote HW, Yorke JA. Gonorrhea transmission dynamics and control. Berlin, New York: Springer-Verlag, 1984.
9. Yorke JA, Hethcote HW, Nold A. Dynamics and control of the transmission of gonorrhea. Sex Transm Dis 1978; 5:51-6.
10. Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002; 78:7-12.
11. Chan CH, McCabe CJ, Fisman DN. Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sex Transm Infect 2012; 88:200-4.
12. White PJ, Ward H, Cassell JA, Mercer CH, Garnett GP. Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. J Infect Dis 2005; 192:824-36.
13. Dietz K, Hadeler KP. Epidemiological models for sexually transmitted diseases. J Math Biol 1988; 26:1-25.
14. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea and Chlamydia using stochastic network simulations. Am J Epidemiol 1996; 144:306-17.
15. Ghani AC, Swinton J, Garnett GP. The role of sexual partnership networks in the epidemiology of gonorrhea. Sex Transm Dis 1997; 24:45-56.
16. Garnett GP, Mertz KJ, Finelli L, Levine WC, St Louis ME. The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Philos Trans R Soc Lond B Biol Sci 1999; 354:787-97.
17. Garnett GP, Bowden FJ. Epidemiology and control and curable sexually transmitted diseases: opportunities and problems. Sex Transm Dis 2000; 27:588-99.
18. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 2002; 8:347-54.
19. Goldstein E, Kirkcaldy RD, Reshef D, et al. Factors related to increasing prevalence of resistance to ciprofloxacin and other antimicrobial drugs in Neisseria gonorrhoeae, United States. Emerg Infect Dis 2012; 18:1290-7.
20. Kirkcaldy RD, Soge O, Papp JR, et al. Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013. Antimicrob Agents Chemother 2015; 59:998-1003.
21. Golparian D, Shafer WM, Ohnishi M, Unemo M. Importance of multidrug efflux pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2014; 58:3556-9.
22. Kunz AN, Begum AA, Wu H, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis 2012; 205:1821-9.
23. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 1997; 94:12106-11.
24. Halloran ME, Longini IM Jr, Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol Rev 1999; 21:73-88.
25. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49:1175-84.
26. Anderson RM, May RM. Infectious diseases of humans dynamics and control. Oxford, New York: Oxford University Press, 1991.
27. Joice R, Lipsitch M. Targeting imperfect vaccines against drug-resistance determinants: a strategy for countering the rise of drug resistance. PLoS One 2013; 8: e68940.
28. Regnier SA, Huels J. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Hum Vaccin Immunother 2014; 10:3737-45.
29. Garnett GP. The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014; 32:1536-42.
30. Centers for Disease Control and Prevention. Figure 15. Gonorrhea-rates of reported cases by county, United States, 2013. Updated 16 December 2014. http://www.cdc.gov/std/stats13/figures/15.htm. Accessed 10 October 2015.
31. Gomez GB, Ward H, Garnett GP. Risk pathways for gonorrhea acquisition in sex workers: can we distinguish confounding from an exposure effect using a priori hypotheses? J Infect Dis 2014; 210(suppl 2):S579-85.
32. Heymans R, Am A, Bruisten SM, et al. Distinct Neisseria gonorrhoeae transmission networks among men who have sex with men in Amsterdam, The Netherlands. J Infect Dis 2012; 206:596-605.
33. Ronn M, White PJ, Hughes G, Ward H. Developing a conceptual framework of seroadaptive behaviors in HIV-diagnosed men who have sex with men. J Infect Dis 2014; 210(suppl 2):S586-93.
34. CDC. Gonococcal Isolate Surveillance Project (GISP) Annual Report 2013. http://www.cdc.gov/std/gisp2013/gisp-2013-all-profiles.pdf. Accessed 14 October 2015.
35. Grad YH, Kirkcaldy RD, Trees D, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis 2014; 14:220-6.
36. Lemey P, Rambaut A, Drummond AJ, Suchard MA. Bayesian phylogeography finds its roots. PLoS Comput Biol 2009; 5:e1000520.
37. Dudas G, Bedford T, Lycett S, Rambaut A. Reassortment between influenza B lineages and the emergence of a coadapted PB1-PB2-HA gene complex. Mol Biol Evol 2015; 32:162-72.
38. Morris SR, Knapp JS, Moore DF, et al. Using strain typing to characterise a fluoroquinolone-resistant Neisseria gonorrhoeae transmission network in southern California. Sex Transm Infect 2008; 84:290-1.
39. Beymer MR, Weiss RE, Bolan RK, et al. Sex on demand: geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles County. Sex Transm Infect 2014; 90:567-72.
40. Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J Math Appl Med Biol 1994; 11:161-92.
41. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 2012; 379:1320-9.
42. Hooper RR, Reynolds GH, Jones OG, et al. Cohort study of venereal disease. I: the risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978; 108:136-44.
43. Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983; 250:3205-9.
44. Hui B, Fairley CK, Chen M, et al. Oral and anal sex are key to sustaining gonorrhoea at endemic levels in MSM populations: a mathematical model. Sex Transm Infect 2015; 91:365-9.
45. Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic gonorrhea in men. Diagnosis, natural course, prevalence and significance. N Engl J Med 1974; 290:117-23.
46. Marrazzo JM, Apicella MA. Neisseria gonorrhoeae (gonorrhea). In: Bennett JE, Dolin RBlaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia, PA: Elsevier/Saunders, 2015:2446-62.
47. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67-74.
48. Turner AN, Reese PC, Ervin M, Davis JA, Fields KS, Bazan JA. HIV, rectal chlamydia, and rectal gonorrhea in men who have sex with men attending a sexually transmitted disease clinic in a midwestern US city. Sex Transm Dis 2013; 40:433-8.
49. Barbee LA, Kerani RP, Dombrowski JC, Soge OO, Golden MR. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56:1539-45.
50. Xiridou M, Soetens LC, Koedijk FD, Van der Sande MA, Wallinga J. Public health measures to control the spread of antimicrobial resistance in Neisseria gonorrhoeae in men who have sex with men. Epidemiol Infect 2015; 143:1575-84.
51. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163-70.